186 related articles for article (PubMed ID: 27604281)
1. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the ASCO Meeting 2016].
Bußmann L; Busch CJ; Knecht R
HNO; 2016 Oct; 64(10):723-30. PubMed ID: 27604281
[TBL] [Abstract][Full Text] [Related]
2. [Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
Gliese A; Busch CJ; Knecht R
HNO; 2016 Oct; 64(10):717-22. PubMed ID: 27624903
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2018 ASCO meeting].
Bußmann L; Münscher A; Busch CJ
HNO; 2018 Dec; 66(12):907-912. PubMed ID: 30377743
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases: Highlights of the ASCO Meeting 2015].
Bußmann L; Busch CJ; Knecht R
HNO; 2015 Sep; 63(9):620-4. PubMed ID: 26319430
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
Busch CJ; Laban S; Knecht R; Hoffmann TK
HNO; 2016 Oct; 64(10):708-16. PubMed ID: 27604282
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy for HNSCC : Quo vadis?].
Döscher J; Busch CJ; Schuler PJ; Laban S
HNO; 2016 Oct; 64(10):700-7. PubMed ID: 27624904
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of recurrent or metastatic head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].
Zeller N; Busch CJ; Schafhausen P; Knecht R; Möckelmann N
HNO; 2014 Nov; 62(11):787-92. PubMed ID: 25298331
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK
HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429
[TBL] [Abstract][Full Text] [Related]
9. [The most important study results of primary chemoradiation for head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2013].
Münscher A; Busch CJ; Schafhausen P; Tribius S; Knecht R
HNO; 2013 Nov; 61(11):905-10. PubMed ID: 24221218
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of recurrent and metastatic squamous cell carcinoma of the head and neck : highlights of the ASCO Meeting 2013].
Hezel M; Kurzweg T; Münscher A; Schafhausen P; Knecht R
HNO; 2013 Nov; 61(11):911-3. PubMed ID: 24221219
[TBL] [Abstract][Full Text] [Related]
11. Novel Treatment Options in Head and Neck Cancer.
Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
[TBL] [Abstract][Full Text] [Related]
12. [Main results of studies on primary therapy of head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].
Gliese A; Busch CJ; Knecht R
HNO; 2014 Nov; 62(11):781-6. PubMed ID: 25274201
[TBL] [Abstract][Full Text] [Related]
13. [New aspects in the treatment of thyroid cancer : Highlights of the ASCO Annual Meeting 2016].
Lörincz BB; Simon C; Möckelmann N; Knecht R
HNO; 2016 Oct; 64(10):736-40. PubMed ID: 27624902
[TBL] [Abstract][Full Text] [Related]
14. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
Schuler PJ; Doescher JC; Laban S; Hoffmann TK
HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Schoppy DW; Sunwoo JB
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
Bauman JE; Cohen E; Ferris RL; Adelstein DJ; Brizel DM; Ridge JA; O'Sullivan B; Burtness BA; Butterfield LH; Carson WE; Disis ML; Fox BA; Gajewski TF; Gillison ML; Hodge JW; Le QT; Raben D; Strome SE; Lynn J; Malik S
Cancer; 2017 Apr; 123(7):1259-1271. PubMed ID: 27906454
[TBL] [Abstract][Full Text] [Related]
17. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
18. Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck.
Shetty AV; Wong DJ
Otolaryngol Clin North Am; 2017 Aug; 50(4):775-782. PubMed ID: 28755705
[TBL] [Abstract][Full Text] [Related]
19. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
20. Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.
Schutt C; Bumm K; Mirandola L; Bernardini G; Cunha N; Tijani L; Nguyen D; Cordero J; Jenkins MR; Cobos E; Kast WM; Chiriva-Internati M
Int Rev Immunol; 2012 Feb; 31(1):22-42. PubMed ID: 22251006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
